Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
American Battery Factory Announces Offtake Agreements for Its Planned Tucson, AZ Gigafactory
-
Aardvark Therapeutics (AARD) Reiterated at Overweight by Cantor Fitzgerald After Q4 Results
-
Surrozen (SRZN) Reiterated at Overweight by Cantor Fitzgerald After Post-Q4 Model Update
-
Cantor Fitzgerald Starts Generate Biomedicines (GENB) at Overweight
-
Form 10-K Cantor Fitzgerald Income For: Dec 31
-
Robinhood Markets (HOOD) PT Lowered to $95 at Cantor Fitzgerald
-
Cantor Fitzgerald Upgrades Coeur Mining Inc (CDE) to Buy
-
Strategy expands stock offering programs with new sales agents
-
Eve Holding (EVEX) Reiterated at Overweight by Cantor Fitzgerald: 'Shares Undervalued'
-
Rocket Lab (RKLB) Reiterated at Overweight by Cantor Fitzgerald on Largest Launch Contract
-
Satellogic (SATL) Reiterated at Overweight by Cantor Fitzgerald on Improving Fundamentals
-
VinFast Auto (VFS) Reiterated at Overweight by Cantor Fitzgerald on FY26 Delivery Target
-
Lucid Group (LCID) Reiterated at Neutral by Cantor Fitzgerald After Midsize Platform Preview
-
Lucid Group (LCID) Reiterated at Neutral by Cantor Fitzgerald After Midsize Platform Preview
-
Rivian Automotive (RIVN) Reiterated at Neutral by Cantor Fitzgerald Amid UBER Tie-Up
-
Nyxoah SA (NYXH) Reiterated at Overweight by Cantor Fitzgerald on US Commercialization
-
SailPoint Technologies (SAIL) Reiterated at Overweight by Cantor Fitzgerald
-
NVIDIA (NVDA) Reiterated at Overweight by Cantor Fitzgerald on Pace of Innovation
-
Cantor Fitzgerald Downgrades Gossamer Bio Inc. (GOSS) to Neutral
-
Nuclear reactor developer X‑Energy files for US IPO
-
US House Democrat blasts Commerce's 'highly concerning' $1.6 billion USA Rare Earth deal
-
Planet Labs (PL) PT Raised to $40 at Cantor Fitzgerald
-
Guardian Metal prices US IPO at $13.50 per share for $60 million
-
Guardian Metal Announces Pricing of Upsized U.S. Initial Public Offering
-
Cantor Fitzgerald: 'We now expect apitegromab to have near complete market share'
-
$8.65 Billion Agricultural Drone Market by 2032 Presents Great Opportunity for Collaboration with Hylio for Battery System Manufacture: KULR Technology Group, Inc. (NYSE American: KULR)
-
Cantor Fitzgerald Reiterates Neutral Rating on WEX Inc. (WEX)
-
Braze Inc (BRZE) 'One of the More Compelling Opportunities in FY27,' Says Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Neutral Rating on 4D Molecular Therapeutics (FDMT)
-
Cantor Fitzgerald Reiterates Overweight Rating on Annexon Biosciences (ANNX)
-
Cantor Fitzgerald Reiterates Overweight Rating on Micron Technology (MU) Following Blowout Quarter
-
Form 424B3 Cantor Fitzgerald Income
-
Orchid Island Capital Announces March 2026 Monthly Dividend and February 28, 2026 RMBS Portfolio Characteristics
-
SailPoint Technologies Holdings (SAIL) PT Lowered to $23 at Cantor Fitzgerald
-
Regan Total Return Income Fund (RCIRX) Named Best Core Plus Bond Fund Over Five Years by LSEG Lipper
-
Oklo (OKLO) Will Be a Big Winner in Coming Energy Transition: Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on VinFast Auto Ltd. (VFS)
-
Cantor Fitzgerald Reiterates Overweight Rating on Trevi Therapeutics (TRVI)
-
Cantor Fitzgerald Reiterates Overweight Rating on Harrow Health (HROW)
-
Apellis Pharmaceuticals (APLS) PT Lowered to $31 at Cantor Fitzgerald
-
Eve Holding Inc. (EVEX) PT Lowered to $6 at Cantor Fitzgerald, Overweight Rating Maintained
-
Fold Holdings (FLD) PT Lowered to $2 at Cantor Fitzgerald on Weaker Crypto Environment
-
CytomX Therapeutics prices $250 million stock offering at $5.30
-
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
-
Microvast (MVST) PT Lowered to $6 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Eledon Pharamceuticals (ELDN)
-
Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
-
Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD)
-
Cantor Fitzgerald Reiterates Overweight Rating on DocGo (DCGO)
-
Cantor Fitzgerald on SailPoint Technologies Holdings (SAIL): 'We Continue to See a Strong Growth Trajectory'

